Search results
Results from the WOW.Com Content Network
McKesson ANZ is a fully owned subsidiary of McKesson Corporation. McKesson expanded its footprint in Australia and New Zealand by acquiring Emendo in November 2012. [63] McKesson ANZ develops and sells healthcare optimization services and software. The company has traditionally been focused on the public markets in Australia and New Zealand.
In early 2017, CoverMyMeds was acquired by McKesson for $1.1 Billion. [3] In late 2018, CoverMyMeds announced the building and development of a new campus in Franklinton, Columbus, Ohio. The new campus is a multimillion-dollar facility designed by the architect firm, Perkins+Will's Dallas studio. [14]
McKesson owns approximately 70% of the new company with the remaining equity stake held by Change Healthcare stockholders. The new company continues to be called Change Healthcare. [33] In October 2018, it was reported that Change Healthcare Corporation hired underwriters and investment banks for a 2018/2019 time-frame initial public offering. [34]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical distributor McKesson has earned a coveted five ...
The lawsuit against McKesson alleged that the distributor improperly attempted to terminate the drug supply agreement on Saturday, just before Rite Aid declared bankruptcy.
In the quest to find great investments, most investors focus on earnings to gauge a company's financial strength. This is a good start, but earnings can be misleading and incomplete. To get a ...
The company has over 800 sales consultants who work through 39 full-service distribution centers providing coverage throughout the United States. [9] As a single source for medical inventory needs, PSS carries over 55,000 different medical products, (70% supplies, 20% equipment, and 10% pharmaceuticals), representing over 1,000 major manufacturers.
For example, in order ProStrakan Group plc, an international pharmaceutical company based in the UK works with McKesson Specialty Care Solutions to administer its FDA-approved Risk Evaluation and Mitigation Strategy (REMS) program for Abstral. [65]